BMRN vs. TAK: A Head-to-Head Stock Comparison

Updated on November 17, 2025

Here’s a clear look at BMRN and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

BMRN is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	BMRN	TAK
Company Name	BioMarin Pharmaceutical Inc.	Takeda Pharmaceutical Company Limited
Country	United States	Japan
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	10.12 billion USD	43.31 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	July 26, 1999	January 5, 2010
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of BMRN and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BMRN vs. TAK: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	BMRN	TAK
5-Day Price Return	0.29%	-0.33%
13-Week Price Return	-7.27%	-0.76%
26-Week Price Return	-11.21%	-4.35%
52-Week Price Return	-21.32%	5.51%
Month-to-Date Return	-1.68%	0.70%
Year-to-Date Return	-19.87%	0.02%
10-Day Avg. Volume	3.20M	5.02M
3-Month Avg. Volume	2.29M	4.58M
3-Month Volatility	25.33%	18.82%
Beta	0.28	0.40

Profitability

Return on Equity (TTM)

BMRN

8.84%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.

TAK

0.47%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

TAK’s Return on Equity of 0.47% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

BMRN vs. TAK: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

BMRN

16.82%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

TAK

0.75%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 0.75% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

BMRN vs. TAK: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

BMRN

19.89%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

TAK

5.56%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

TAK’s Operating Profit Margin of 5.56% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

BMRN vs. TAK: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	BMRN	TAK
Return on Equity (TTM)	8.84%	0.47%
Return on Assets (TTM)	7.13%	0.23%
Net Profit Margin (TTM)	16.82%	0.75%
Operating Profit Margin (TTM)	19.89%	5.56%
Gross Profit Margin (TTM)	81.32%	64.60%

Financial Strength

Current Ratio (MRQ)

BMRN

4.83

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

TAK

1.37

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

TAK’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

BMRN vs. TAK: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BMRN

0.10

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

TAK

0.65

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BMRN vs. TAK: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

BMRN

-21.18

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

TAK

1.96

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

BMRN vs. TAK: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	BMRN	TAK
Current Ratio (MRQ)	4.83	1.37
Quick Ratio (MRQ)	3.10	0.76
Debt-to-Equity Ratio (MRQ)	0.10	0.65
Interest Coverage Ratio (TTM)	-21.18	1.96

Growth

Revenue Growth

BMRN vs. TAK: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BMRN vs. TAK: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BMRN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TAK

4.67%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

With a Dividend Yield of 4.67%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

BMRN vs. TAK: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

BMRN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TAK

124.94%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

BMRN vs. TAK: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	BMRN	TAK
Dividend Yield (TTM)	0.00%	4.67%
Dividend Payout Ratio (TTM)	0.00%	124.94%

Valuation

Price-to-Earnings Ratio (TTM)

BMRN

19.22

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

BMRN’s P/E Ratio of 19.22 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

TAK

200.30

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

At 200.30, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

BMRN vs. TAK: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

BMRN

3.23

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.23 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

TAK

1.50

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.50 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

BMRN vs. TAK: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

BMRN

1.72

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

TAK

0.96

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

TAK’s P/B Ratio of 0.96 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

BMRN vs. TAK: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	BMRN	TAK
Price-to-Earnings Ratio (TTM)	19.22	200.30
Price-to-Sales Ratio (TTM)	3.23	1.50
Price-to-Book Ratio (MRQ)	1.72	0.96
Price-to-Free Cash Flow Ratio (TTM)	12.11	7.18